IP Library Granted Patent US 8,071,139
Granted Patent B2
US 8,071,139 · App. 12/554,364 · Granted Dec 6, 2011

Treatment of damaged skin

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,071,139
App. No.
12/554,364
Granted
Dec 6, 2011
Kind
B2
Abstract

A medicament for treating skin is described. It comprises essentially of bulbine frutescens, centella asiatica and a phenol derived from olive oil preferably oleuropein. The medicament may be used in the treatment of scars formed during surgery. It may also be used cosmeceutically in the treatment of aged skin where it may be used with phosphatidylserine. The medicament can also act in conjunction with anti-acne treatment to diminish scarring from the acne condition.

Claims (62)

1. A gel medicament for topical application to damaged skin, said medicament consisting essentially of:

an extract of bulbine frutescens in an amount from about 9% to about 11% mass per mass of the medicament;

an extract of Centella asiatica in an amount from about 0.1% to about 2% mass per mass of the medicament;

a phenol extracted from a source selected from the group consisting of olive leaf and olive oil in an amount from about 0.18% to about 0.3% mass per volume of the medicament, wherein said phenol comprises oleuropein;

dimethicone;

water;

propylene glycol;

glycerol-polyethylene glycol oxystearate;

poloxamer; and

phenoxyethanol.

2. The medicament of claim 1 , wherein the damaged skin is damaged by a wound, a scar, acne, or aging.

3. The medicament of claim 2 , wherein the wound is produced during a surgical procedure.

4. The medicament of claim 1 , wherein application of the medicament to said damaged skin reduces inflammation.

5. The medicament of claim 1 , wherein topical application of the medicament to said damaged skin produces an occlusive dressing without the use of microporous tape.

6. The medicament of claim 1 , wherein said medicament facilitates formation of a barrier that protects the damaged skin from environmental influences and provides support for said damaged skin.

7. A gel medicament for topical application to damaged skin, said medicament consisting essentially of:

an extract of bulbine frutescens in an amount from about 9% to about 11.0% mass per mass of the medicament;

an extract of Centella asiatica in an amount from about 0.1% to about 2% mass per mass of the medicament;

a phenol extracted from a source selected from the group consisting of olive leaf and olive oil in an amount from about 0.18% to about 0.3% mass per volume of the medicament, wherein said phenol comprises oleuropein; and

dimethicone;

water;

propylene glycol;

glycerol-polyethylene glycol oxystearate;

poloxamer;

phenoxyethanol; and

phosphatidylserine.

8. The medicament of claim 7 , wherein the damaged skin is damaged by a wound, a scar, acne, or aging.

9. The medicament of claim 8 , wherein the wound is produced during a surgical procedure.

10. The medicament of claim 7 , wherein application of the medicament to said damaged skin reduces inflammation.

11. The medicament of claim 7 , wherein topical application of the medicament to said damaged skin produces an occlusive dressing without the use of microporous tape.

12. The medicament of claim 7 , wherein said medicament facilitates formation of a barrier that protects the damaged skin from environmental influences and provides support for said damaged skin.

13. A gel medicament for topical application to damaged skin, said medicament consisting essentially of:

an extract of bulbine frutescens in an amount from about 9% to about 11.0% mass per mass of the medicament;

an extract of Centella asiatica in an amount from about 0.1% to about 2% mass per mass of the medicament;

a phenol extracted from a source selected from the group consisting of olive leaf and olive oil in an amount from about 0.18% to about 0.3% mass per volume of the medicament, wherein said phenol comprises oleuropein;

dimethicone;

water;

propylene glycol;

glycerol-polyethylene glycol oxystearate;

poloxamer;

phenoxyethanol; and

a vitamin.

14. The medicament of claim 13 , wherein the damaged skin is damaged by a wound, a scar, acne, or aging.

15. The medicament of claim 13 , wherein application of the medicament to said damaged skin reduces inflammation.

16. The medicament of claim 13 , wherein topical application of the medicament to said damaged skin produces an occlusive dressing without the use of microporous tape.

17. The medicament of claim 13 , wherein said medicament facilitates formation of a barrier that protects the damaged skin from environmental influences and provides support for said damaged skin.

18. A gel medicament for topical application to damaged skin, said medicament consisting essentially of:

an extract of bulbine frutescens in an amount from about 9% to about 11.0% mass per mass of the medicament;

an extract of Centella asiatica in an amount from about 0.1% to about 2% mass per mass of the medicament;

a phenol extracted from a source selected from the group consisting of olive leaf and olive oil in an amount from about 0.18% to about 0.3% mass per volume of the medicament, wherein said phenol comprises oleuropein;

dimethicone;

water;

propylene glycol;

glycerol-polyethylene glycol oxystearate;

poloxamer;

phenoxyethanol; and

lactic acid.

19. A gel medicament for topical application to damaged skin, said medicament consisting essentially of:

an extract of bulbine frutescens in an amount from about 9% to about 11.0% mass per mass of the medicament;

an extract of Centella asiatica in an amount from about 0.1% to about 2% mass per mass of the medicament;

a phenol extracted from a source selected from the group consisting of olive leaf and olive oil in an amount from about 0.18% to about 0.3% mass per volume of the medicament, wherein said phenol comprises oleuropein; and

dimethicone.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 5, 2023
From: WIDGEROW, ALAN DAVID
To: ALLERGAN, INC.
Reel/Frame 065132/0349 →
Priority Claims (2)
ZA 2008/08004 · Sep 18, 2008 · national
ZA 2009/04000 · Jun 8, 2009 · national
Continuity (2)
Provisional Application 61094170 · Sep 4, 2008
Related Publication 20100062085A1 · Mar 11, 2010